| 000 | 01895 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517160450.0 | ||
| 264 | 0 | _c20180208 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1525-1438 | ||
| 024 | 7 |
_a10.1097/IGC.0000000000001052 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan Haaften, Caroline | |
| 245 | 0 | 0 |
_aChemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents. _h[electronic resource] |
| 260 |
_bInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society _c10 2017 |
||
| 300 |
_a1571-1578 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aBRCA1 Protein _xgenetics |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 |
_aCystadenocarcinoma, Serous _xdrug therapy |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenes, BRCA1 |
| 650 | 0 | 4 | _aGerm-Line Mutation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 |
_aLactones _xadministration & dosage |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPhthalazines _xadministration & dosage |
| 650 | 0 | 4 |
_aPiperazines _xadministration & dosage |
| 650 | 0 | 4 |
_aSesquiterpenes _xadministration & dosage |
| 700 | 1 | _avan Eendenburg, Jaap | |
| 700 | 1 | _aBoot, Arnoud | |
| 700 | 1 | _aCorver, Willem E | |
| 700 | 1 | _aHaans, Lucien | |
| 700 | 1 | _avan Wezel, Tom | |
| 700 | 1 | _aTrimbos, J Baptist | |
| 773 | 0 |
_tInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society _gvol. 27 _gno. 8 _gp. 1571-1578 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/IGC.0000000000001052 _zAvailable from publisher's website |
| 999 |
_c27268048 _d27268048 |
||